Key result
Belimumab increases mucocutaneous improvement to 59% vs 49% with placebo at 52 weeks.
Why the study?
Does belimumab improve mucocutaneous and vasculitis manifestations in adults with active systemic lupus erythematosus?
Does belimumab improve mucocutaneous and vasculitis manifestations in adults with active systemic lupus erythematosus?
Absolute Event Rate: 59% vs 49%
p-value: p=<.0001
Belimumab added to standard therapy significantly improves mucocutaneous and vasculitis manifestations in patients with active systemic lupus erythematosus compared to standard therapy alone.
ObjectiveTo investigate the effects of belimumab (BEL) on systemic lupus erythematosus (SLE) mucocutaneous and vasculitis manifestations.MethodsThis post hoc, integrated Belimumab Summary of Lupus Efficacy (Be-SLE) analysis pooled data from five international Phase 3, randomized, placebo (PBO)-controlled BEL trials (BLISS-52 [NCT00424476; conducted in 2007-2009], BLISS-76 [NCT00410384; 2007-2009], BLISS-SC [NCT01484496; 2011-2015], North East Asia [NCT01345253; 2011-2015], EMBRACE [NCT01632241; 2013-2018]). Adults with active SLE and Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score ≥6 (BLISS-52, BLISS-76) or ≥8 (BLISS-SC, North East Asia, EMBRACE), randomized to BEL (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or PBO, plus standard therapy (ST) were included. Mucocutaneous and vasculitis manifestations (listed below) were measured (baseline and every 4 weeks) for 52 weeks using SELENA-SLEDAI and British Isles Lupus Assessment Group (BILAG).ResultsOf 3086 patients (BEL, n = 1869; PBO, n = 1217), 85% (BEL and PBO) by SELENA-SLEDAI and 58% (BEL) and 62% (PBO) by BILAG (moderate or severe activity) had mucocutaneous manifestations, and <10% had vasculitis at baseline. At Week 52, significantly more BEL-treated than PBO-treated patients demonstrated improvements in SELENA-SLEDAI (59% vs 49%; p < .0001) and BILAG (54% vs 43%; p < .0001) mucocutaneous domains. Significant differences between-treatment favored BEL at Week 52 for resolution of all SELENA-SLEDAI items (vasculitis, rash, alopecia, and mucosal ulcers), and nine of 20 BILAG items (mild maculopapular eruption, localized active discoid lesions, mild alopecia, small mucosal ulceration, malar erythema, subcutaneous nodules, swollen fingers, major cutaneous vasculitis including ulcers, and minor cutaneous vasculitis).ConclusionPatients with SLE treated with BEL plus ST experienced significant improvements in most mucocutaneous and vasculitis manifestations compared with patients receiving PBO plus ST. These data provide additional support for the use of BEL in SLE and show that it is associated with skin improvements.
No takes yet. Share an insight, caveat, or question.
Manzi et al. (2025) studied systemic lupus erythematosus (SLE) (n=3,086). belimumab vs. placebo plus standard therapy was evaluated on improvements in SELENA-SLEDAI mucocutaneous domains at Week 52 (p=<.0001). Belimumab plus standard therapy significantly improved SELENA-SLEDAI mucocutaneous domains compared to placebo at 52 weeks (59% vs 49%; p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: